The stock opened at Rs 463 and has seen over seven-fold jump in trading volumes. A combined 5.43 million shares representing about 17% free-float equity of the company changed hands on the counter till 1050 hours on the BSE and NSE.
The stock of drug maker has underperformed the market so far in 2014, gained 1.7% compared to 6% rise in benchmark S&P BSE Sensex till yesterday.
Wockhardt is facing various regulatory issues, including USFDA import alert at Waluj and Chikalthana units and is working to resolve these issues at the earliest to limit the financial impact, reports suggest.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)